Maleki Vareki S - Search Results

1

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".

Rytelewski M, Ferguson PJ, Maleki Vareki S, Figueredo R, Vincent M, Koropatnick J. Rytelewski M, et al. Among authors: maleki vareki s. Mol Ther Nucleic Acids. 2013 Mar 12;2(3):e78. doi: 10.1038/mtna.2013.7. Mol Ther Nucleic Acids. 2013. PMID: 23481354 Free PMC article.

2

Differential regulation of simultaneous antitumor and alloreactive CD8(+) T-cell responses in the same host by rapamycin.

Maleki Vareki S, Harding MJ, Waithman J, Zanker D, Shivji AN, Rytelewski M, Mazzuca DM, Yekta MA, Chen W, Schell TD, Haeryfar SM. Maleki Vareki S, et al. Am J Transplant. 2012 Jan;12(1):233-9. doi: 10.1111/j.1600-6143.2011.03811.x. Epub 2011 Oct 25. Am J Transplant. 2012. PMID: 22026814 Free PMC article.

3

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin.

Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, Min W, Zheng X, Koropatnick J. Maleki Vareki S, et al. Oncotarget. 2014 May 15;5(9):2778-91. doi: 10.18632/oncotarget.1916. Oncotarget. 2014. PMID: 24784564 Free PMC article.

4

BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J. Rytelewski M, et al. Among authors: maleki vareki s. Mol Oncol. 2014 Dec;8(8):1429-40. doi: 10.1016/j.molonc.2014.05.017. Epub 2014 Jun 6. Mol Oncol. 2014. PMID: 24974076 Free PMC article.

5

siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.

Di Cresce C, Figueredo R, Rytelewski M, Maleki Vareki S, Way C, Ferguson PJ, Vincent MD, Koropatnick J. Di Cresce C, et al. Among authors: maleki vareki s. Oncotarget. 2015 Sep 8;6(26):22397-409. doi: 10.18632/oncotarget.4272. Oncotarget. 2015. PMID: 26087398 Free PMC article.

6

IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.

Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, Vincent M, Min W, Zheng X, Koropatnick J. Maleki Vareki S, et al. PLoS One. 2015 Nov 18;10(11):e0143435. doi: 10.1371/journal.pone.0143435. eCollection 2015. PLoS One. 2015. PMID: 26579709 Free PMC article.

7

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.

Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Rytelewski M, et al. Among authors: maleki vareki s. Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883. Oncotarget. 2016. PMID: 26959114 Free PMC article.

8

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Salim KY, Maleki Vareki S, Danter WR, Koropatnick J. Salim KY, et al. Among authors: maleki vareki s. Oncotarget. 2016 Jul 5;7(27):41363-41379. doi: 10.18632/oncotarget.9133. Oncotarget. 2016. PMID: 27150056 Free PMC article.

9

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA. Petrova PS, et al. Among authors: maleki vareki s. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17. Clin Cancer Res. 2017. PMID: 27856600

10

Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.

Maleki Vareki S, Salim KY, Danter WR, Koropatnick J. Maleki Vareki S, et al. PLoS One. 2018 Jan 24;13(1):e0191766. doi: 10.1371/journal.pone.0191766. eCollection 2018. PLoS One. 2018. PMID: 29364966 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters